Merck's Earnings Report Masks Loss, Margin Compression

Merck's recent earnings report has left investors wondering about the company's future prospects. Despite a 5% increase in revenue to $16.6 billion, Merck posted a net loss of $1.3 billion due to a multi-billion dollar acquisition charge.

The charge was related to the Terns deal, which pushed earnings into a loss and forced the company to lower its full-year EPS guidance to $2.66-$2.76 per share.

While some analysts see this as an opportunity for Merck to expand its margins through reinvestment, others are concerned about the company's dependence on a few blockbuster drugs and its aggressive deal-making strategy.